📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. (2022)

First Author: Sharpe BP

Attributed to: Role of heparin binding growth factors in O.viverrini induced Cholangiocarcinoma (O-CCA) development, progression and angiogenesis funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.xcrm.2022.100541

PubMed Identifier: 35732148

Publication URI: http://europepmc.org/abstract/MED/35732148

Type: Journal Article/Review

Volume: 3

Parent Publication: Cell reports. Medicine

Issue: 6

ISSN: 2666-3791